Biosig Technologies (NASDAQ:STEX) Issues Earnings Results

Biosig Technologies (NASDAQ:STEX) announced its quarterly earnings results on Tuesday. The company reported ($8.23) earnings per share (EPS) for the quarter, FiscalAI reports.

Biosig Technologies Price Performance

Shares of NASDAQ:STEX opened at $1.13 on Wednesday. Biosig Technologies has a 1-year low of $0.40 and a 1-year high of $14.11. The stock’s 50-day moving average price is $2.31. The company has a market cap of $200.84 million, a PE ratio of -0.83 and a beta of 1.60.

Insider Buying and Selling

In other Biosig Technologies news, major shareholder Frank Giustra bought 100,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average cost of $3.17 per share, with a total value of $317,000.00. Following the completion of the purchase, the insider owned 1,278,205 shares in the company, valued at approximately $4,051,909.85. The trade was a 8.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Morgan Lee Lekstrom acquired 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was acquired at an average price of $2.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the chairman directly owned 122,500 shares in the company, valued at $306,250. This trade represents a 19.51% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 1,267,011 shares of company stock valued at $3,825,628 over the last three months. Company insiders own 52.73% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised shares of Biosig Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings assumed coverage on Biosig Technologies in a report on Friday, January 23rd. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.